Literature DB >> 32221518

Impact of the Current US Preventive Services Task Force Recommendations for Cervical Cancer Screening in Young Women 21 to 29 Years Old.

C Paul Morris1,2, Sayanan Chowsilpa1,3, Sara Mustafa1, Isaac Chan4, Daniel Miller1, Zahra Maleki1, Erika F Rodriguez1.   

Abstract

OBJECTIVES: In 2012, the US Preventive Services Task Force decreased the recommended frequency of cervical cytology screening to once every 3 years and recommended against testing women younger than 21 years regardless of sexual history. We evaluated the impact of this in 21 to 29-year-old women at a tertiary care academic medical center in 2011 and 2017.
METHODS: We retrospectively analyzed Papanicolaou test results at two time points in 21- to 29-year-old women.
RESULTS: There was a decrease in the number of high-grade lesions in 21- to 25-year-old women (odds ratio [OR], 0.36) from 2011 to 2017. Within the 26- to 29-year-old patient group, there was a trend toward a higher percentage of high-grade squamous intraepithelial lesion (HSIL) in 2017 compared to 2011 on cytology, which did not reach statistical significance (OR, 1.46). However, follow-up histologic specimens showed a higher percentage of HSIL in 2017 compared to 2011 in this age group (OR, 2.16).
CONCLUSIONS: Our findings suggest that the cervical cancer screening guidelines introduced in 2012 have not had a detrimental impact on the outcomes of cervical cancer screening for 21- to 25-year-old women. However, we need to continue monitoring the effects of decreased screening in 26- to 29-year-old women. © American Society for Clinical Pathology, 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Cervical cancer screening; HPV; HPV 16; HPV 18; High-grade intraepithelial lesion; Pap test; USPSTF

Year:  2020        PMID: 32221518     DOI: 10.1093/ajcp/aqaa012

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  2 in total

1.  Cost-effectiveness and accuracy of cervical cancer screening with a high-risk HPV genotyping assay vs a nongenotyping assay in China: an observational cohort study.

Authors:  Binhua Dong; Lihua Chen; Wenyu Lin; Yingying Su; Xiaodan Mao; Diling Pan; Guanyu Ruan; Huifeng Xue; Yafang Kang; Pengming Sun
Journal:  Cancer Cell Int       Date:  2020-08-28       Impact factor: 5.722

2.  Cervical Screening Practices and Outcomes for Young Women in Response to Changed Guidelines in Calgary, Canada, 2007-2016.

Authors:  Sayeeda Amber Sayed; Christopher Naugler; Guanmin Chen; James A Dickinson
Journal:  J Low Genit Tract Dis       Date:  2021-01-01       Impact factor: 3.842

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.